Teva Pharmaceuticals Usa, Inc: Octreotide Acetate For Injectable Suspension, For Gluteal Intramuscular Use, 30 Mg, Single-dose
Recall Summary Teva Pharmaceuticals is recalling Octreotide Acetate for Injectable Suspension (30 mg) nationwide because the manufacturer failed to maintain proper quality controls that ensure the medication is sterile. This injectable medication is used to treat certain hormone-related conditions and was distributed across all U.S. states and Washington, D.C.
- Recalling firm
- Teva Pharmaceuticals USA, Inc
- Product
- Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9262-08.
- Reason
- Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Classification
- Class II
- Category
- drug recall
- Country
- United States
- Agency
- U.S. Food and Drug Administration
- Recall date
- 2026-03-17
- Status
- Ongoing
- Areas affected
- AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, ...
- Distribution
- Nationwide in the USA
Official recall notice from U.S. Food and Drug Administration
Recall details on Nibble Recalls: https://trynibble.app/recalls/a7f50e7e-d865-4089-b299-faedd532beff